NCT03070691 2017-05-05
Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2/3 Withdrawn
Novartis
Maastricht University Medical Center
Bispebjerg Hospital